Cortical Amyloid Burden Relates to Basal Forebrain Volume in Subjective Cognitive Decline.


Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2023
Historique:
medline: 23 10 2023
pubmed: 28 8 2023
entrez: 28 8 2023
Statut: ppublish

Résumé

Atrophy of cholinergic basal forebrain (BF) nuclei is a frequent finding in magnetic resonance imaging (MRI) volumetry studies that examined patients with prodromal or clinical Alzheimer's disease (AD), but less clear for individuals in earlier stages of the clinical AD continuum. To examine BF volume reductions in subjective cognitive decline (SCD) participants with AD pathologic changes. The present study compared MRI-based BF volume measurements in age- and sex-matched samples of N = 24 amyloid-positive and N = 24 amyloid-negative SCD individuals, based on binary visual ratings of Florbetaben positron emission tomography (PET) measurements. Additionally, we assessed associations of BF volume with cortical amyloid burden, based on semiquantitative Centiloid (CL) analyses. Group differences approached significance for BF total volume (p = 0.061) and the Ch4 subregion (p = 0.059) only, showing the expected relative volume reductions for the amyloid-positive subgroup. There were also significant inverse correlations between BF volumes and CL values, which again were most robust for BF total volume and the Ch4 subregion. The results are consistent with the hypothesis that amyloid-positive SCD individuals, which are considered to represent a transitional stage on the clinical AD continuum, already show incipient alterations of BF integrity. The negative association with a continuous measure of cortical amyloid burden also suggests that this may reflect an incremental process. Yet, further research is needed to evaluate whether BF changes already emerge at "grey zone" levels of amyloid accumulation, before amyloidosis is reliably detected by PET visual readings.

Sections du résumé

BACKGROUND
Atrophy of cholinergic basal forebrain (BF) nuclei is a frequent finding in magnetic resonance imaging (MRI) volumetry studies that examined patients with prodromal or clinical Alzheimer's disease (AD), but less clear for individuals in earlier stages of the clinical AD continuum.
OBJECTIVE
To examine BF volume reductions in subjective cognitive decline (SCD) participants with AD pathologic changes.
METHODS
The present study compared MRI-based BF volume measurements in age- and sex-matched samples of N = 24 amyloid-positive and N = 24 amyloid-negative SCD individuals, based on binary visual ratings of Florbetaben positron emission tomography (PET) measurements. Additionally, we assessed associations of BF volume with cortical amyloid burden, based on semiquantitative Centiloid (CL) analyses.
RESULTS
Group differences approached significance for BF total volume (p = 0.061) and the Ch4 subregion (p = 0.059) only, showing the expected relative volume reductions for the amyloid-positive subgroup. There were also significant inverse correlations between BF volumes and CL values, which again were most robust for BF total volume and the Ch4 subregion.
CONCLUSIONS
The results are consistent with the hypothesis that amyloid-positive SCD individuals, which are considered to represent a transitional stage on the clinical AD continuum, already show incipient alterations of BF integrity. The negative association with a continuous measure of cortical amyloid burden also suggests that this may reflect an incremental process. Yet, further research is needed to evaluate whether BF changes already emerge at "grey zone" levels of amyloid accumulation, before amyloidosis is reliably detected by PET visual readings.

Identifiants

pubmed: 37638433
pii: JAD230141
doi: 10.3233/JAD-230141
doi:

Substances chimiques

Amyloid 0
Amyloidogenic Proteins 0
Amyloid beta-Peptides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1013-1028

Auteurs

Marcel Daamen (M)

German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.

Lukas Scheef (L)

German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Department for Diagnostic and Interventional Radiology, University Hospital Bonn, Bonn, Germany.
RheinAhrCampus, University of Applied Sciences Koblenz, Remagen, Germany.

Shumei Li (S)

German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.

Michel J Grothe (MJ)

Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.

Florian C Gaertner (FC)

Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.

Ralph Buchert (R)

Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Katharina Buerger (K)

German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilian University Munich, Munich, Germany.

Laura Dobisch (L)

German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.

Alexander Drzezga (A)

German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Institute of Neuroscience and Medicine (INM-2), Molecular Organization of the Brain, Forschungszentrum Jülich, Jülich, Germany.

Markus Essler (M)

Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.

Michael Ewers (M)

Institute for Clinical Radiology, Ludwig-Maximilians-University Munich, Munich, Germany.

Klaus Fliessbach (K)

German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Department of Neurodegenerative Disease and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.

Ana Lucia Herrera Melendez (AL)

Institute of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Stefan Hetzer (S)

Berlin Center of Advanced Neuroimaging, Charité -Universitätsmedizin Berlin, Berlin, Germany.

Daniel Janowitz (D)

Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilian University Munich, Munich, Germany.

Ingo Kilimann (I)

German Center for Neurodegenerative Diseases (DZNE), Rostock/Greifswald, Germany.
Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany.

Bernd Joachim Krause (BJ)

Department of Nuclear Medicine, Rostock University Medical Centre, Rostock, Germany.

Catharina Lange (C)

Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Christoph Laske (C)

German Center for Neurodegenerative Diseases (DZNE), Tuebingen, Germany.
Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany.

Matthias H Munk (MH)

German Center for Neurodegenerative Diseases (DZNE), Tuebingen, Germany.
Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany.

Oliver Peters (O)

Institute of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.

Josef Priller (J)

German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany.
University of Edinburgh and UK Dementia Research Institute, Edinburgh, UK.

Alfredo Ramirez (A)

German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Department of Neurodegenerative Disease and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.
Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
Department of Psychiatry and Psychotherapy, Division of Neurogenetics and Molecular Psychiatry, Faculty of Medicine and University Hospital Cologne, University of Cologne, Medical Faculty, Cologne, Germany.
Department of Psychiatry & Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San Antonio, TX, USA.

Matthias Reimold (M)

Department of Nuclear Medicine and Clinical Molecular Imaging, Eberhard-Karls-University, Tübingen, Germany.

Axel Rominger (A)

Department of Nuclear Medicine, Ludwig-Maximilian-University Munich, Munich, Germany.
Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Ayda Rostamzadeh (A)

Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Sandra Roeske (S)

German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.

Nina Roy (N)

German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.

Klaus Scheffler (K)

Department for Biomedical Magnetic Resonance, University of Tübingen, Tübingen, Germany.

Anja Schneider (A)

German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Department of Neurodegenerative Disease and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.

Annika Spottke (A)

German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Department of Neurology, University Hospital Bonn, Bonn, Germany.

Eike Jakob Spruth (EJ)

German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Stefan J Teipel (SJ)

German Center for Neurodegenerative Diseases (DZNE), Rostock/Greifswald, Germany.
Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany.

Michael Wagner (M)

German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Department of Neurodegenerative Disease and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.

Emrah Düzel (E)

German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany.

Frank Jessen (F)

German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Henning Boecker (H)

German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Department for Diagnostic and Interventional Radiology, University Hospital Bonn, Bonn, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH